Back to Annual Meeting

Back to Annual Meeting

Abstract #149285

• Audio (mp3) recording
• Slides (pdf) or Handout
• Multimedia recording

Michele Forzley, JD, MPH, Health Law Institute, Weidner College of Law, 3120 Lee Street, Silver Spring, MD 20910, 301 565 0680, mforzley@comcast.net

Product donations from the pharmaceutical and medical products industries to NGOs in destinations where poverty or crisis or a less than optimal health system result in limited drug access have been ongoing since as early as the 1950s when Eli Lilly donated products to an NGO. There has not been a systematic review of medical product donations since 1999, although they have continued and the volume and dollar value has flourished to a multi- billion per year industry. The industry began as a result of excess product inventory, when and if available, but as such donations are not a reliable source of supply. Pharmaceutical and medical supply corporate philanthropy has evolved to include program types in addition to excess inventory, including "produce-to-give", annual allotment and signature programs such as the Merck Mectizan program. Based on a literature review and donor information, the key elements of program types will be analyzed to consider how these programs help or hinder drug access at programmatic, national and global levels. Other factors impede the ability of donations to provide access to drugs, such as customs duties, product registration requirements, the nature of incentives such as public relations and tax deductions, lack of quantification and specification by recipients. Policy implications call for national and international regulatory solutions and a shift in corporate philanthropic policies. The session will briefly review the current WHO Guidelines on Medical Product Donations and recommend policy changes to the Guidelines to cover vaccines, and bio-engineered and genetic medical products.

Learning Objectives:

• Articulate what medical product donations are, the types of programs and how each can support drug access.
• Summarize the WHO Guidelines on Medical Product Donations.
• Evaluate the limitations and opportunities of donations.

Keywords: Access, Medicine

Presenting author's disclosure statement:

Any relevant financial relationships? No
Any institutionally-contracted trials related to this submission?

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.

• Audio (mp3) recording
• Slides (pdf) or Handout
• Multimedia recording